ZenenBio Completes Construction of Xenotransplantation Integrated Research Complex 'ZenenCore Center'

Completion Ceremony of Zennecore Center.

[Asia Economy Reporter Lee Gwan-joo] Zenen Bio announced on the 7th that it has completed the construction of the Zenen Core Center, a comprehensive xenotransplantation research complex.

The Zenen Core Center is a comprehensive R&D center based on the core facilities of the 'Non-clinical Trial Center' and 'GMP Manufacturing Facility,' enabling research and development, manufacturing, and non-clinical trials for product verification of xenotransplantation products. It is located in the Dream Tech Industrial Complex in Pyeongtaek-si, Gyeonggi Province, with a total floor area of 21,060.56㎡.

One of the core facilities of the Zenen Core Center, the 'Non-clinical Trial Center,' conducts non-clinical animal trials to evaluate the safety and efficacy of xenotransplantation products, laying the groundwork for clinical application and verifying the quality of products after market release.

In addition to xenotransplantation research, a CRO business performing non-clinical trials for biopharmaceuticals and advanced medical device companies will be conducted concurrently. Zenen Bio, which possesses a bioanalysis center capable of rodent CRO business, now operates the Non-clinical Trial Center capable of primate CRO business, enabling the provision of comprehensive CRO services for all processes necessary for drug development.

Exterior view of Zenen Core Center.

Also, the 'GMP Manufacturing Facility' is responsible for producing both prototypes needed for non-clinical and clinical procedures, such as xenogeneic tissues and cells, and final products for actual sales. This will be the first private manufacturing facility for large-scale mass production of xenotransplantation products.

Zenen Bio plans to accelerate xenotransplantation research and development and related product development with the completion of the Zenen Core Center, while maximizing synergy effects with the Transgenic Center operating on a nearby site. The Zenen Core Center will handle efficacy evaluation and product manufacturing of xenotransplantation product raw materials, while the Transgenic Center will be responsible for raw material development and production, performing all processes necessary for xenotransplantation product development.

Kim Sung-joo, CEO of Zenen Bio, said, “With recent successful xenotransplantation research results announced one after another in the United States and other countries, the commercialization of xenotransplantation is rapidly approaching. We are very pleased to establish a comprehensive xenotransplantation R&D center in line with the global trend.” He added, “Now that a one-stop platform covering the entire xenotransplantation process has become possible, we will do our best to solve the global shortage of transplant organs and help more patients.”